IDEXX Laboratories, Inc. (IDXX)
| Market Cap | 55.40B |
| Revenue (ttm) | 4.17B |
| Net Income (ttm) | 1.03B |
| Shares Out | 79.85M |
| EPS (ttm) | 12.60 |
| PE Ratio | 55.06 |
| Forward PE | 49.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279,285 |
| Open | 689.82 |
| Previous Close | 691.05 |
| Day's Range | 687.46 - 698.29 |
| 52-Week Range | 356.14 - 769.98 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 700.50 (+0.96%) |
| Earnings Date | Feb 2, 2026 |
About IDXX
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference... [Read more]
Financial Performance
In 2024, IDEXX Laboratories's revenue was $3.90 billion, an increase of 6.46% compared to the previous year's $3.66 billion. Earnings were $887.87 million, an increase of 5.07%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IDXX stock is "Buy." The 12-month stock price target is $700.5, which is an increase of 0.96% from the latest price.
News
MoneyShow's Best Investment Ideas For 2026: Part 5
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an...
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
WESTBROOK, Maine--(BUSINESS WIRE)--ImageVue DR50 Plus introduces high-definition diagnostic imaging at the lowest dose of radiation, accelerating diagnosis and improving staff safety.
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
WESTBROOK, Maine--(BUSINESS WIRE)--Cancer Dx Panel expansion and inVue Dx FNA cytology rollout advance veterinary cancer care, enabling comprehensive mast cell tumor testing for dogs.
IDEXX Announces CEO Succession
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the promotion of Michael (Mike) Erickson, PhD, to President an...
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial r...
Final Trades: Palo Alto Networks, Capital One, Idexx Labs and the XLB
CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may b...
Baron Asset Fund Q3 2025 Performance Review
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. From a sector perspective, stock selection in IT...
IDEXX Laboratories: A Strong Third Quarter With Good Future Prospects
IDEXX Laboratories (IDXX) continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21...
Final Trades: Meta, S&P Global and Idexx Lab
The Investment Committee give you their top stocks to watch for the second half.
IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. ( IDXX) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jay Mazelsky - President, CEO & Director Confer...
Idexx Stock Pops on Earnings. Pet Health Is Booming.
Vet visits are down, but growing revenue per visit is more than making up for it, the company says.
Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook
IDEXX Laboratories Inc.‘s (NASDAQ:IDXX) stock is trading higher on Monday after it reported better-than-expected third-quarter financial results and raised its 2025 forecast.
IDEXX raises annual forecasts as pet owners spend more on preventive care
IDEXX Laboratories raised its full-year profit and revenue forecasts on Monday after reporting better third-quarter results than last year, as the pet diagnostics maker banks on owners spending more o...
IDEXX Laboratories Announces Third Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company repor...
IDEXX Laboratories Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will release earnings results for the third quarter, before the opening bell on Monday, Nov. 3.
IDEXX Laboratories to Release 2025 Third Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 third quarter financial results for Mond...
IDEXX Laboratories Elects Karen Peacock to Board of Directors
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Direct...
IDEXX Laboratories, Inc. (IDXX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Jay Mazelsky - President, CEO & Director Andrew Emers...
IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and ...
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
S&P 500 Gains and Losses Today: Retail Sector Stocks Rise Amid Rate Cut Hopes
Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised...
IDEXX Laboratories, Inc. (IDXX) Q2 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President,...